In the future, it could be interesting to study if target therapy with inhibitors of the PI3K/AKT/mTOR pathways used to treat symptoms of APDS could also play a role in reducing the risk of ovarian tumorigenesis or, in association with conventional chemotherapy, in the first-line treatment of tumors in APDS patients. The gene discussed is MTOR; the disease is activated PI3K-delta syndrome.